Net Cash Provided by (Used in) Financing Activities of AbbVie Inc. from 31 Mar 2016 to 31 Dec 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.
Summary
AbbVie Inc. annual and quarterly Net Cash Provided by (Used in) Financing Activities in USD history and change rate from 31 Mar 2016 to 31 Dec 2025.
  • AbbVie Inc. Net Cash Provided by (Used in) Financing Activities for the quarter ending 31 Mar 2025 was $1,258,000,000, a 112% decline year-over-year.
  • AbbVie Inc. annual Net Cash Provided by (Used in) Financing Activities for 2025 was $12,724,000,000, a 144% decline from 2024.
  • AbbVie Inc. annual Net Cash Provided by (Used in) Financing Activities for 2024 was $5,211,000,000, a 70% increase from 2023.
  • AbbVie Inc. annual Net Cash Provided by (Used in) Financing Activities for 2023 was $17,222,000,000, a 31% increase from 2022.
Source SEC data
View on sec.gov
Net Cash Provided by (Used in) Financing Activities, Annual (USD)
Net Cash Provided by (Used in) Financing Activities, YoY Annual Change (%)
Net Cash Provided by (Used in) Financing Activities, Quarterly (USD)
Net Cash Provided by (Used in) Financing Activities, YoY Quarterly Change (%)

AbbVie Inc. Annual Net Cash Provided by (Used in) Financing Activities (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2025 $12,724,000,000 -$7,513,000,000 -144% 01 Jan 2025 31 Dec 2025 10-K 20 Feb 2026 2025 FY
2024 $5,211,000,000 +$12,011,000,000 +70% 01 Jan 2024 31 Dec 2024 10-K 20 Feb 2026 2025 FY
2023 $17,222,000,000 +$7,581,000,000 +31% 01 Jan 2023 31 Dec 2023 10-K 20 Feb 2026 2025 FY
2022 $24,803,000,000 -$5,764,000,000 -30% 01 Jan 2022 31 Dec 2022 10-K 14 Feb 2025 2024 FY
2021 $19,039,000,000 -$7,538,000,000 -66% 01 Jan 2021 31 Dec 2021 10-K 20 Feb 2024 2023 FY
2020 $11,501,000,000 -$30,209,000,000 -161% 01 Jan 2020 31 Dec 2020 10-K 17 Feb 2023 2022 FY
2019 $18,708,000,000 +$33,104,000,000 01 Jan 2019 31 Dec 2019 10-K 18 Feb 2022 2021 FY
2018 $14,396,000,000 -$8,884,000,000 -161% 01 Jan 2018 31 Dec 2018 10-K 19 Feb 2021 2020 FY
2017 $5,512,000,000 -$1,584,000,000 -40% 01 Jan 2017 31 Dec 2017 10-K 21 Feb 2020 2019 FY
2016 $3,928,000,000 01 Jan 2016 31 Dec 2016 10-K 27 Feb 2019 2018 FY

AbbVie Inc. Quarterly Net Cash Provided by (Used in) Financing Activities (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q1 2025 $1,258,000,000 -$12,077,000,000 -112% 01 Jan 2025 31 Mar 2025 10-Q 09 May 2025 2025 Q1
Q1 2024 $10,819,000,000 +$17,011,000,000 01 Jan 2024 31 Mar 2024 10-Q 09 May 2025 2025 Q1
Q1 2023 $6,192,000,000 +$780,000,000 +11% 01 Jan 2023 31 Mar 2023 10-Q 03 May 2024 2024 Q1
Q1 2022 $6,972,000,000 -$3,798,000,000 -120% 01 Jan 2022 31 Mar 2022 10-Q 05 May 2023 2023 Q1
Q1 2021 $3,174,000,000 -$752,000,000 -31% 01 Jan 2021 31 Mar 2021 10-Q 06 May 2022 2022 Q1
Q1 2020 $2,422,000,000 +$2,961,000,000 +55% 01 Jan 2020 31 Mar 2020 10-Q 07 May 2021 2021 Q1
Q1 2019 $5,383,000,000 -$2,874,000,000 -115% 01 Jan 2019 31 Mar 2019 10-Q 08 May 2020 2020 Q1
Q1 2018 $2,509,000,000 -$715,000,000 -40% 01 Jan 2018 31 Mar 2018 10-Q 03 May 2019 2019 Q1
Q1 2017 $1,794,000,000 -$575,000,000 -47% 01 Jan 2017 31 Mar 2017 10-Q 04 May 2018 2018 Q1
Q1 2016 $1,219,000,000 01 Jan 2016 31 Mar 2016 10-Q 05 May 2017 2017 Q1
* An asterisk sign (*) next to the value indicates that the value is likely invalid.